Peak IL-6 levels seen in patients in dose escalation. (A) Summary of peak IL-6 levels and incidence/grade of CRS by fixed weekly dose. Peak IL-6 and CRS manifestations occurring within 24 hours after the first dose were strongly dose related, with doses ≥0.7 μg/kg associated with an intolerable rate and severity of CRS. (B) Summary of mean of log10 IL-6 levels in cohorts 1D and -1D. Frequent dosing within the first week was associated with enhanced tolerability and remarkable suppression of peak IL-6 levels. 7A, cohort 7 Part A; 8A, cohort 8 Part A; 9A, cohort 9 Part A; 10A, cohort 10, Part A.